Renin-angiotensin system in chronic renal allograft dysfunction

Contributions to Nephrology

Volumn 135, Issue , 2001, Pages 222-234

  Shihab, Fuad S ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ALLOTRANSPLANTATION; CHRONIC DISEASE; DRUG EFFECT; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; NEEDLE BIOPSY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOPSY, NEEDLE; CHRONIC DISEASE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0035538369     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000060169     Document Type: Article

References (44)

1. Paul LC: Chronic allograft nephropathy: An update. Kidney Int 1999;56:783-793.
2. Womer KL, Vella JP, Sayegh MH: Chronic allograft dysfunction: Mechanisms and new approaches to therapy. Semin Nephrol 2000;20:126-147.
3. Solez K, Vincenti F, Filo RS: Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine. Transplantation 1998;66:1736-1740.
4. Shihab FS: Cyclosporine nephropathy: Pathophysiology and clinical impact. Semin Nephrol 1996;16:536-547.
5. Shihab FS, Tanner AM, Shao Y, Weffer MI: Expression of TGF-β1 and matrix proteins is elevated in rats with chronic rejection. Kidney Int 1996;50:1904-1913.
6. Shihab FS, Yamamoto T, Nast CC, Cohen AH, Noble NA, Gold LI, Border WA: Transforming growth factor-β and matrix protein expression in acute and chronic rejection of human renal allografts. J Am Soc Nephrol 1995;6:286-294.
7. Jain S, Furness PN, Nicholson ML: The role of transforming growth factor beta in chronic renal allograft nephropathy. Transplantation 2000;69:1759-1766.
8. Paul LC, Benediktsson H: Post-transplant hypertension and chronic renal allograft failure. Kidney Int 1995;48:S34-S37.
9. Shihab FS, Andoh TF, Tanner AM, Noble NA, Border WA, Franceschini N, Bennett WM: Role of transforming growth factor-β1 in experimental chronic cyclosporine nephropathy. Kidney Int 1996;49:1141-1151.
10. Shihab FS, Bennett WM, Tanner AM, Andoh TF: Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation 1997;64:1829-1837.
11. Bresticker M, Nelson J, Huang C, Wolf J, Anderson B: Plasma renin activity in renal transplant patients with hypertension. Am J Hypertens 1991;4:623-626.
12. Wagner J, Volk S, Haufe CC, Ciechanowicz A, Paul M, Ritz E: Renin gene expression in human kidney biopsies from patients with glomerulonephritis or graft rejection. J Am Soc Nephrol 1995;5:1469-1475.
13. Becker BN, Jacobson LM, Becker YT, Radke NA, Heisey DM, Oberley TD, Pirsch JD, Sollinger HW, Brazy PC, Kirk AD: Renin-angiotensin gene expression in post-transplant hypertension predicts allograft function. Transplantation 2000;69:1485-1491.
14. Shihab FS, Bennett WM, Tanner AM, Andoh TF: Angiotensin II blockade decreases TGF-β1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997;52:660-673.
15. Bantle JP, Nath KA, Sutherland DE, Najarian JS, Ferris TF: Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients. Arch Int Med 1985;145:505-508.
16. Gardiner DS, Watson MA, Junor BR, Briggs JD, Lindop GBM: The effect of conversion from cyclosporin A to azathioprine on renin-containing cells in renal allograft biopsies. Nephrol Dial Transplant 1991;6:363-367.
17. Sharma AM, Beige J, Distler A: Role of genetic variants of the renin-angiotensin system in chronic renal allograft injury. Kidney Int 1998;53:1461-1465.
18. Barocci S, Ginevri F, Valente U, Torre F, Gusmano R, Nocera A: Correlation between angiotensin-converting enzyme gene insertion/deletion polymorphism and kidney graft long-term outcome in pediatric recipients. Transplantation 1999;67:534-538.
19. Wolf G, Neilson EG: Angiotensin II induces cellular hypertrophy in cultured murine proximal tubular cells. Am J Physiol 1990;259:F768-F777.
20. Szabo A, Lutz J, Schleimer K, Antus B, Hamar P, Phillipp T, Heemann U: Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Kidney Int 2000;57:982-991.
21. Campistol JM, Iñigo P, Jimenez W, Lario S, Clesca PH, Oppenheimer F, Rivera F: Losartan decreases plasma levels of TGF-β1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999;56:714-719.
22. Kagami S, Kuhara T, Okada K, Kuroda Y, Border WA, Noble NA: Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 1997;51:664-671.
23. Asberg A, Attramadal H, Midtvedt K, Sund S, Hartmann A, Berg KJ: Gene expression of the renal endothelin system in renal transplant recipients on cyclosporine A based immunosuppression. Transplantation 1999;67:1056-1060.
24. Orth SR, Odoni G, Amann K, Strzelczyk P, Raschack M, Ritz E: The ET(A) receptor blocker LU 135252 prevents chronic transplant nephropathy in the 'Fisher to Lewis' model. J Am Soc Nephrol 1999;10:387-391.
25. De Nicola L, Blantz RC, Gabbai FB: Nitric oxide and angiotensin II: Glomerular and tubular interaction in the rat. J Clin Invest 1992;89:1248-1256.
26. Gardner MP, Houghton DC, Andoh TF, Lindsley J, Bennett WM: Clinically relevant doses and blood levels produce experimental cyclosporine nephrotoxicity when combined with nitric oxide inhibition. Transplantation 1996;61:1506-1512.
27. Shihab FS, Yi H, Bennett WM, Andoh TF: Effect of nitric oxide modulation on TGF-β1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int 2000;58:1174-1185.
28. Ziai F, Nagano H, Kusaka M, Coito AJ, Troy JL, Nadeau KC, Rennke HG, Tilney NL, Brenner BM, MacKenzie HS: Renal allograft protection with losartan in Fisher→Lewis rats: Hemodynamics, macrophages, and cytokines. Kidney Int 2000;57:2618-2625.
29. Pilmore HL, Eris JM, Painter DM, Bishop GA, McCaughan GW. Vascular endothelial growth factor expression in human chronic renal allograft rejection. Transplantation 1999;67:929-933.
30. Shihab FS, Bennett WM, Yi H, Andoh TF: Expression of vascular endothelial growth factor and its receptors Flt-1 and Flk-1 in chronic cyclosporine nephrotoxicity. Transplantation, in press.
31. Laine J, Etelamaki P, Holmberg C, Dunkel L: Apoptotic cell death in human chronic renal allograft rejection. Transplantation 1997;63:101-105.
32. Cigola E, Kajstura J, Li B, Meggs LG, Anversa P: Angiotensin II activated programmed cell death in vitro. Exp Cell Res 1997;231:363-371.
33. Sharma VK, Bologa RM, Li B, Xu GP, Lagman M, Hiscock W, Mouradian J, Wang J, Serur D, Rao VK, Suthanthiran M: Molecular executors of cell death - differential intrarenal expression of Fas ligand, Fas, granzyme B, and perforin during acute and/or chronic rejection of human renal allografts. Transplantation 1996;62:1860-1866.
34. Shihab FS, Andoh TF, Tanner AM, Yi H, Bennett WM: Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis. Kidney Int 1999;56:2147-2159.
35. Vianello A, Mastrosimone S, Calconi G, Gatti PL, Calzavara P, Maresca MC: The role of hypertension as a damaging factor for kidney grafts under cyclosporine therapy. Am J Kidney Dis. 1993;21:S79-S83.
36. Opelz G, Wujciak T, Ritz E: Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998;53:217-222.
37. Azuma H, Nadeau K, Mackenzie HS, Brenner BM, Tilney NL: Nephron mass modulates the hemodynamic, cellular, and molecular response of the rat renal allograft. Transplantation 1997;63:519-528.
38. van der Schaaf MR, Hene RJ, Floor M, Blankestijn PJ, Koomans HA: Hypertension after renal transplant. Calcium channel or converting enzyme blockade? Hypertension 1995;25:77-81.
39. Rell K, Linde J, Morzycka-Michalik M, Gaciong Z, Lao M: Effect of enalapril on proteinuria after kidney transplantation. Transpl Int 1993;6:213-217.
40. Traindl O, Falger S, Reading S, Banyai M, Liebisch B, Gisinger J, Templ E, Mayer G, Kovarik J: The effects of lisinopril on renal function in proteinuric renal transplant recipients. Transplantation 1993;55:1309-1313.
41. Barnas U, Schmidt A, Haas M, Oberbauer R, Mayer G: The effects of prolonged angiotensin-converting enzyme inhibition on excretory kidney function and proteinuria in renal allograft recipients with chronic progressive transplant failure. Nephrol Dial Transplant 1996;11:1822-1824.
42. Paredes D, Sola R, Guirado L, Ibeas J, Agraz I, Vizcarra D, Algaba F: Treatment of kidney transplants with chronic rejection using angiotensin-converting enzyme inhibitors. Transplant Proc 1997;29:2587-2588.
43. Mourad G, Ribstein J, Mimran A: Converting enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int 1993;43:419-425.
44. Stigant CE, Cohen J, Vivera M, Zaltzman JS: ACE inhibitors and angiotensin II antagonists in renal transplantation: An analysis of safety and efficacy. Am J Kidney Dis 2000;35:58-63.